Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Alan Lau"'
Autor:
Alan Lau, Susan Galbraith, Sonja J. Gill, Mark J. O'Connor, Joshua Armenia, Jacqueline H. L. Fok, Conchita Vens, Rebecca L. Lloyd, Jonathan Cairns, Jenni Nikkilä, Christopher J. Bakkenist, Paul W. G. Wijnhoven
Publikováno v:
Mol Cancer Ther
Radiotherapy is an effective anticancer treatment, but combinations with targeted agents that maximize efficacy while sparing normal tissue are needed. Here, we assess the radiopotentiation profiles of DNA damage response inhibitors (DDRi) olaparib (
Autor:
Keun-Wook Lee, Natasha Lukashchuk, Andrew Goldwin, Bienvenu Loembe, Graeme Parr, Irene Kang, Tobias Arkenau, R Roylance, Mario Campone, Claire Smith, Wassim Abida, Andrew J. Pierce, Duncan I. Jodrell, Alan Lau, Elhan Sanay, Sophie Postel-Vinay, Juanita Lopez, Sunyoung Rha, Emma Dean, Matthew G Krebs, Seock-Ah Im
Publikováno v:
Cancer Research. 81:PS11-18
Background: Alterations in BRCA1/2 are associated with ~9% of all BCs. Ola (a poly ADP-ribose polymerase inhibitor [PARPi]) is approved for treating pts with HER2-negative metastatic BC with germline BRCA mutation (gBRCAm), demonstrating an improveme
Autor:
Matthew J. Sale, Luis Tobalina, Alan Lau, Elizabeth A. Coker, Elisabetta Leo, Andrew J. Pierce, Anderson T. Wang, Violeta Serra, Mark J. O'Connor, Tarrion Baird, Gemma N Jones, Tudor Petreus, Patricia Jaaks, Joshua Armenia, Claudia Winkler, Mathew J. Garnett
Publikováno v:
British Journal of Cancer. 124:951-962
Background Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinic
Autor:
J. Carl Barrett, Lei Zhao, Amanda G. Paulovich, Richard G. Ivey, Zena Wilson, Antonio Ramos-Montoya, Martine P. Roudier, Jeffrey R. Whiteaker, Gareth Hughes, Alan Lau, Claire Rooney, Elaine Cadogan, Rajesh Odedra, Andrew J. Pierce, William J. Howat, Lucy H. Young, Elizabeth A. Harrington, Nicola Griffin, Antonio Garcia-Trinidad, Gemma N Jones
Publikováno v:
British Journal of Cancer
Background AZD0156 and AZD6738 are potent and selective inhibitors of ataxia-telangiectasia-kinase (ATM) and ataxia-telangiectasia-mutated and Rad3-related (ATR), respectively, important sensors/signallers of DNA damage. Methods We used multiplexed t
Autor:
Neil H. James, Alan Lau, Antonio Ramos-Montoya, Gemma N Jones, Giuditta Illuzzi, Paul W. G. Wijnhoven, Katarzyna Falenta, Rebecca L. Lloyd, Lucy H. Young, Zena Wilson, Jonathan Stott, Emma Dean, Christophe D. Chabbert
Publikováno v:
Oncogene
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA at single-strand breaks, leading
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2baf3724e07bec854228e122b048829f
https://www.repository.cam.ac.uk/handle/1810/322860
https://www.repository.cam.ac.uk/handle/1810/322860
Autor:
Niall M. B. Martin, Bastiaan Evers, Charlotte Knights, Janneke E. Jaspers, Jos Jonkers, Attilla Ting, Henry Brown, Keith W. Caldecott, Sven Rottenberg, Rajesh Odedra, Lenka Oplustil O'Connor, Robert Hugh Bradbury, Aaron Cranston, David Alan Rudge, Mark J. O'Connor, Marina Pajic, Louise J. Jones, Alan Lau, Stuart L. Rulten
Publikováno v:
Cancer Research. 76:6084-6094
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Autor:
Zena Wilson, James W.T. Yates, Matthew G Krebs, Kevin J. Harrington, Andrew J. Pierce, Alan Lau, Emma Dean, Magnus T. Dillon, Gemma N Jones
Publikováno v:
Cancer Research. 80:LB-104
Ceralasertib is a potent and selective ATP competitive inhibitor of ataxia telangiectasia and Rad3 related (ATR) in clinical development as monotherapy and in combination with olaparib (Lynparza) and durvalumab (Imfinzi) in patients with advanced sol
Autor:
Bienvenu Loembe, Amit M. Oza, Mei Lin W. Ah-See, Alan Lau, Nisha Kurian, Andrew J. Pierce, Si-Houy Lao-Sirieix, Graeme Parr, Emma Dean
Publikováno v:
Journal of Clinical Oncology. 38:TPS6104-TPS6104
TPS6104 Background: Ovarian cancer is the leading cause of death from gynecological cancers in the USA, and the fifth most common cause of cancer death in women. Ola is a PARPi approved for first-line maintenance treatment of BRCA-mutated advanced ov
Autor:
Ellen Wientjens, Niall M. B. Martin, Jos Jonkers, Ariena Kersbergen, Alan Lau, Liesbeth van Deemter, Sven Rottenberg, Serge A.L. Zander, Mark J. O'Connor, James H. Doroshow, Jiuping Ji, Ute Boon, Rinske Drost, Piet Borst, Amal Aly, Aaron Cranston, Janneke E. Jaspers, Shridar Ganesan, Wendy Sol
Publikováno v:
Cancer Discovery; Vol 3
Cancer discovery, 3(1), 68-81. American Association for Cancer Research Inc.
Cancer discovery, 3(1), 68-81. American Association for Cancer Research Inc.
Inhibition of PARP is a promising therapeutic strategy for homologous recombination–deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inh
Autor:
Matthew G Krebs, Kevin J. Harrington, S.Y. Amy Cheung, Alienor Berges, Simon Smith, Alan Lau, Brunella Felicetti, Andrew J. Pierce, James W.T. Yates, Emma Dean, Simon J. Hollingsworth, Christine Stephens, Nathan Standifer
Publikováno v:
Cancer Research. 78:CT118-CT118
Introduction: AZD6738 is a potent inhibitor of the ATR protein kinase that is being tested in patients with solid malignancies. In Phase I dose escalation studies, AZD6738 was dosed as monotherapy (continuous schedule from 40 - 480 mg per day), or in